Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 90 member A25, pseudogene (FAM90A25P), is classified as an **unprocessed pseudogene**, annotated in the human genome with the Ensembl accession ENSG00000251402[1][3][7]. As a pseudogene, it is a genomic DNA sequence similar to a known gene but presumed nonfunctional and does not encode a functional protein. Although some pseudogenes participate in gene regulation or may generate non-coding RNAs, FAM90A25P lacks demonstrated protein-coding capacity and is not considered a therapeutic target, receptor, enzyme, transporter, or transcription factor. No evidence supports its use as a biomarker, nor are drugs known to target it. Currently, there are no reports linking it to specific diseases or therapeutic safety issues[2][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 90 member A25, pseudogene (FAM90A25P).